A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating

Posted on:
Key Points

(Some companies also allow payment via Klarna and other buy now, pay later services for their compounded products, lowering financial barriers even further.) Many of the telehealth companies ship the drugs after a quick questionnaire, with no lab work or doctor visit required, which means new patients can get meds within days...

When asked whether Eli Lilly is confident it has supply to accommodate compounded tirzepatide patients switching over to its products, Forbes sent the following statement via email: All doses of Mounjaro and ZepboundLillys FDA-approved tirzepatide medicationshave been available since early August..

It is simply financially inaccessible, Bertel says.. The FDA does not recommend taking compounded versions of GLP-1 medications and has advised potential patients about its concerns over dosing errors and adverse effects related to compounded semaglutide and tirzepatide..

Whats more, with many compounded tirzepatide patients likely to shift to taking compounded semaglutide, its a crisis that may only get more intense when semaglutide, too, is removed from the FDA shortage list..

(It is unclear when that will happen, but there is evidence it may not be far off: Novo Nordisk, which makes Wegovy and Ozempic using semaglutide, has recently increased supply of most dosages of the meds in the US.) The cost of drugs does not factor into whether they are in official shortage or not, but the affordability of these medications is directly connected to how accessible many patients find them..